How did TSVT's revenue and expenses shift in Q4 2024?

**2seventy bio's Revenue and Expenses in Q4 2024:**
1. **Revenue Shift**: 2seventy bio reported a revenue of $13.53 million for the third quarter of 2024, an increase of 13% from the previous year's $12.03 million. This indicates a positive trend in revenue growth, although it missed analyst estimates by 7%.
2. **Net Loss Improvement**: The company narrowed its net loss to $9.93 million in Q3 2024, a significant reduction from the $71.64 million net loss in the same period the previous year. This suggests substantial improvement in profitability.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|TSVT|TSVT.O|2seventy bio|20240101-2024|Collaborative Arrangement|1.9744E7|185|
|TSVT|TSVT.O|2seventy bio|20240101-2024|Collaborative Arrangement|1.9744E7|185|
|TSVT|TSVT.O|2seventy bio|20240101-2024|Collaborative Arrangement|9060000|185|
|TSVT|TSVT.O|2seventy bio|20240101-2024|Collaborative Arrangement|4714000|185|
|TSVT|TSVT.O|2seventy bio|20240101-2024|Collaborative Arrangement|4714000|185|
|TSVT|TSVT.O|2seventy bio|20240101-2024|Service|7721000|185|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|TSVT|TSVT.O|2seventy bio|2024 Q1|-12.020161204568172|-5.2673E7|185|
|TSVT|TSVT.O|2seventy bio|2024 Q2|159.11045641378982|2.4879E7|185|
|TSVT|TSVT.O|2seventy bio|2024 Q3|86.1344537815126|-9933000|185|
|TSVT|TSVT.O|2seventy bio|2024 Q4|65.64710851430785|-1.952E7|185|

|code|Ticker|Name|Date|RSI|MACD|market_code|
|---|---|---|---|---|---|---|
|TSVT|TSVT.O|2seventy bio|20241231|34.9884|-0.0056|185|

|code|Ticker|Name|Date|KDJ|market_code|
|---|---|---|---|---|---|
|TSVT|TSVT.O|2seventy bio|20241231|37.8695|185|

3. **Expense Management**: 2seventy bio has been effective in managing its expenses, as reflected by the 86% reduction in net loss from the previous year. This indicates a strong cost control measures.
4. **Cash Position**: The company ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities, which provides a solid financial base for operations and potential strategic moves.

In conclusion, 2seventy bio demonstrated positive revenue growth and significant improvement in net profitability in Q4 2024, alongside effective expense management and a strong cash position.